Sep 29 |
RAPT Therapeutics, Inc. (RAPT): Worst 52-Week Low Stock to Buy Now
|
Sep 25 |
RAPT Therapeutics, Inc. (RAPT) Stock Falls Following FDA Setback; Short Sellers Cite Unprofitability
|
Aug 8 |
RAPT Therapeutics GAAP EPS of -$0.71 beats by $0.05
|
Aug 8 |
RAPT Therapeutics Reports Second Quarter 2024 Financial Results
|
Jul 24 |
RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus
|
Jul 22 |
RAPT Therapeutics to cut 40% of workforce to save cash
|
Jun 21 |
Should You Sell Your Stake in RAPT Therapeutics (RAPT)?
|
Jun 14 |
Down -15.94% in 4 Weeks, Here's Why Rapt Therapeutics (RAPT) Looks Ripe for a Turnaround
|
May 29 |
Rapt Therapeutics (RAPT) Loses -47.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
May 20 |
RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity
|